Holen Sie sich die Stockscreener-App
7.16
3.17%
0.22
Vorhandelsmarkt:
7.20
0.04
+0.56%
Schlusskurs vom Vortag:
$6.94
Offen:
$6.95
24-Stunden-Volumen:
946.95K
Relative Volume:
0.76
Marktkapitalisierung:
$388.63M
Einnahmen:
$1.02B
Nettoeinkommen (Verlust:
$-757.20M
KGV:
-0.4851
EPS:
-14.76
Netto-Cashflow:
$-257.90M
1W Leistung:
+3.32%
1M Leistung:
+15.11%
6M Leistung:
-34.13%
1J Leistung:
-37.52%
1-Tages-Spanne:
$6.93
$7.19
1-Wochen-Bereich:
$6.74
$7.43
52-Wochen-Spanne:
$4.02
$15.10
Emergent Biosolutions Inc Stock (EBS) Company Profile
Firmenname
Emergent Biosolutions Inc
Sektor
Telefon
240-631-3200
Adresse
300 PROFESSIONAL DR, GAITHERSBURG, MD
Vergleichen Sie EBS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
7.16 | 376.15M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
151.19 | 68.05B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.55 | 46.58B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.65 | 43.71B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.29 | 18.40B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
297.89 | 13.23B | 2.99B | 1.21B | 1.13B | 25.06 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-22 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-03-07 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Underweight |
| 2023-08-29 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-04-10 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-03-17 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-11-10 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-04-29 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-11-08 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-05-05 | Herabstufung | Argus | Buy → Hold |
| 2021-04-07 | Eingeleitet | The Benchmark Company | Buy |
| 2021-02-24 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral |
| 2020-07-31 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-09-04 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | Hochstufung | Goldman | Neutral → Buy |
| 2018-08-03 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-06-13 | Eingeleitet | Argus | Buy |
| 2018-04-25 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | Eingeleitet | Goldman | Neutral |
| 2018-01-16 | Bestätigt | Chardan Capital Markets | Buy |
| 2016-06-28 | Bestätigt | Singular Research | Buy |
| 2016-04-15 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-03-28 | Eingeleitet | Singular Research | Buy |
| 2016-02-19 | Eingeleitet | Wells Fargo | Outperform |
| 2014-05-15 | Eingeleitet | Summer Street Research | Buy |
| 2011-05-31 | Bestätigt | WBB Securities | Strong Buy |
| 2011-01-10 | Bestätigt | Wedbush | Outperform |
| 2010-11-05 | Bestätigt | Wedbush | Outperform |
| 2010-08-18 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | Bestätigt | Caris & Company | Buy |
Alle ansehen
Emergent Biosolutions Inc Aktie (EBS) Neueste Nachrichten
Emergent BioSolutions Inc. Stock Analysis and ForecastExplosive wealth accumulation - jammulinksnews.com
What drives Emergent BioSolutions Inc. stock priceConsistent wealth multiplication - jammulinksnews.com
Is Emergent BioSolutions Inc. a good long term investmentMassive portfolio appreciation - PrintWeekIndia
Is MDU Resources Group Inc. a good long term investmentHigh-yield investments - jammulinksnews.com
AGYS Stock Analysis and ForecastAccelerated financial growth - Autocar Professional
What analysts say about Emergent BioSolutions Inc. stockFree Investment Community - jammulinksnews.com
Hawthorn Bancshares Inc. Stock Analysis and ForecastBreakthrough capital growth - jammulinksnews.com
What drives EMX Royalty Corporation stock priceSkyrocketing returns - jammulinksnews.com
Emergent Signs $174M Manufacturing Deal For AstraZeneca’s Covid-19 Candidate - TipRanks
What makes Emergent BioSolutions Inc. stock price move sharplyPotential Rocket List - beatles.ru
Lobbying Update: $440,000 of EMERGENT BIOSOLUTIONS INC lobbying was just disclosed - Nasdaq
Emergent BioSolutions to Report Second Quarter 2025 Financial Re - GuruFocus
Emergent BioSolutions Inc. to Host Q2 2025 Financial Results Conference Call on August 6 - Nasdaq
Emergent BioSolutions Q2 2025 Earnings Call Scheduled for August 6: Key Details Inside - Stock Titan
Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025 - TradingView
Government Contract Update: $52M payment to EMERGENT BIOSOLUTIONS CANADA INC - Nasdaq
Emergent BioSolutions signs contract modification award for CNJ-016 - MSN
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Benchmark Co. Maintains Emergent BioSolutions(EBS.US) With Buy Rating, Maintains Target Price $12 - 富途牛牛
Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts - The Manila Times
Emergent BioSolutions Stock Rises After New US Order For Smallpox Complication Therapy - Stocktwits
Emergent BioSolutions secures contract modification for smallpox treatment By Investing.com - Investing.com South Africa
Emergent BioSolutions secures contract modification for smallpox treatment - Investing.com Australia
Emergent BioSolutions (EBS) Expands Smallpox Vaccine Contract wi - GuruFocus
Emergent BioSolutions (EBS) Secures Smallpox Preparedness Contra - GuruFocus
Emergent BioSolutions Gets $51.9 Million Contract Modification for Smallpox Preparedness - MarketScreener
Emergent BioSolutions stock rises on government contract modification By Investing.com - Investing.com Canada
Emergent BioSolutions stock rises on government contract modification - Investing.com India
Emergent BioSolutions Secures Contract Modification for Additional VIGIV Doses to Support U.S. Smallpox Preparedness - Quiver Quantitative
Emergent BioSolutions Strengthens US Biodefense Arsenal with $51.9M Government Contract - Stock Titan
Lobbying Update: $40,000 of EMERGENT BIOSOLUTIONS lobbying was just disclosed - Quiver Quantitative
Is Emergent BioSolutions (NYSE:EBS) Using Debt In A Risky Way? - simplywall.st
Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate - The Manila Times
Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® ( - GuruFocus
Emergent BioSolutions adds KLOXXADO to online naloxone platform By Investing.com - Investing.com UK
Investors Can Still File Late Claims in Emergent BioSolutions Settlement - TradingView
Emergent BioSolutions Inc.(NYSE: EBS) added to Russell 3000E Value Index - MarketScreener
Is Emergent BioSolutions, Inc. overvalued or undervalued? - MarketsMojo
Emergent BioSolutions secures $62.4 million contract for botulism antitoxin By Investing.com - Investing.com South Africa
Emergent BioSolutions Awarded $62.4 Million Contract Modification for BAT® Antitoxin by U.S. Department of Health and Human Services - Quiver Quantitative
Emergent BioSolutions Announces Addition to Russell 3000® Index - The Manila Times
Emergent BioSolutions to join Russell 3000 Index after market close June 27 - Investing.com Nigeria
EBS Stock Up 1.4% after 1-Day Win Streak - Trefis
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030 - GlobeNewswire
Government Contract Update: $62M payment to EMERGENT BIOSOLUTIONS CANADA INC - Nasdaq
BRIEF—LigaChem links up with NovaRock - The Pharma Letter
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Emergent BioSolutions (EBS) Investors with $100k+ Losses to Contact Its Attorneys Now, Securities Fraud Case Pending, Firm Investigating CEO’s Insider Sales - ACCESS Newswire
Emergent BioSolutions at Jefferies Conference: Strategic Transformation By Investing.com - Investing.com Canada
Finanzdaten der Emergent Biosolutions Inc-Aktie (EBS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.09%
0.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):